Skip to main content
Home

Language & Country Selector for Desktop

language-selector-globe United States | en

Choose Location

  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
  • Argentina | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Latin America | es
  • Mexico | es
  • United States | en
  • Venezuela | es
  • Australia | en
  • Bangladesh | en
  • Hong Kong S.A.R. | zh
  • India | en
  • Indonesia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Malaysia | en
  • Pakistan | en
  • Philippines | en
  • Taiwan | zh
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hungary | hu
  • Ireland | en
  • Italy | it
  • Latvia | lv
  • Lithuania | lt
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Global | en
  • Novartis Foundation | en
  • Sandoz | en
  • Egypt | en
  • South Africa | en
  • Turkey | tr

Language & Country Selector for Mobile

language-selector-globe US

Choose Location

Americas Asia Pacific Europe International Middle East & Africa
  • Argentina | es
  • Australia | en
  • Austria | de
  • Bangladesh | en
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Egypt | en
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Global | en
  • Greece | el
  • Hong Kong S.A.R. | zh
  • Hungary | hu
  • India | en
  • Indonesia | en
  • Ireland | en
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Latin America | es
  • Latvia | lv
  • Lithuania | lt
  • Mainland China | zh
  • Malaysia | en
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Novartis Foundation | en
  • Pakistan | en
  • Philippines | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Sandoz | en
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • South Africa | en
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Taiwan | zh
  • Turkey | tr
  • United Kingdom | en
  • United States | en
  • Venezuela | es
    • About 
      • Novartis in the US 
        • Company at a Glance 
        • By the Numbers 
        • Diversity and Inclusion 
        • Pay Transparency-EPIC 
        • Our Code of Ethics 
      • Strategy 
      • Diversity and Inclusion 
        • Ensuring Equity 
        • The Spirit of Inclusivity 
        • Toward a better society 
        • Parental Leave 
        • Standing for Racial Equity and Justice as One Novartis 
        • Novartis US EEO / D&I Report 2021 
        • Supplier Diversity 
      • People and Culture 
      • Products 
      • Country Leadership Team 
      • External Funding 
      • Contact Us 
      Woman scientist in lab About
    • Patients and Caregivers 
      • Novartis Commitment to Patients and Caregivers 
      • Patient Assistance 
      • Diseases 
      • Participating in Clinical Trials 
      • Patient Perspectives 
      • Adverse Event Reporting 
      • The STEP Program 
        • Sickle Cell Disease (SCD) 
        • Program Overview 
        • Multiple Sclerosis (MS) 
        • Cancer 
        • Application for Funding to Help Address Health Disparities 
        • Health Disparities 
      Patient smiling at doctor image Patients and Caregivers
    • Healthcare Professionals 
      • Novartis Pipeline 
      • Novartis Clinical Trials 
      • Adverse Event Reporting 
      Two doctors examining X-ray Healthcare Professionals
    • ESG 
      • Ethical Behavior 
        • Code of Ethics 
        • SpeakUp 
        • PhRMA Code on Interactions with Healthcare Professionals 
        • Business Principles 
      • Ethics, Risk and Compliance 
        • Compliance Program 
        • State Laws 
        • Corporate Integrity Agreement 
        • Payments to HCPs & HCOs 
        • Enhanced Verification Request 
      • Corporate Responsibility 
        • Population Health 
        • Novartis in Society US Reports 
        • Novartis US Foundation 
        • Environmental Sustainability 
        • People and Communities 
      • Beacon of Hope 
        • Beacon of Hope: Measurable solutions for health equity 
      Novartis East Hanover Campus Landscaping ESG
    • News 
      • News Archive 
      • Statements 
      • Stories 
      • Contacts 
      Co-workers having a meeting News
    • Careers 
      • Career Search 
      • Meet the Teams 
      • Early Career 
      • Personal Growth 
      • How We Work 
      • Employee Benefits 
      • Diversity and Inclusion 
      • Awards & Recognition 
      Meeting in Atrium Careers
    • Coronavirus 
      coronavirus covid 19 hero image_0 Coronavirus
    Novartis East Hanover Campus East Village Promenade Home
  1. Home
  2. News
  3. News Archive
News Archive Navigation
  • All
  • Media Releases
  • Stories
  • Statements
icon
Showing 353 results

January 2008

  • Media ReleaseJan 21, 2008
    Video and Photo: Tekturna HCT®, a Single-tablet Combination of Tekturna®* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
    - Tekturna HCT combines first approved direct renin inhibitor with the diuretic hydrochlorothiazide (HCTZ) in a single tablet- Data show combination of Tekturna and HCTZ resulted in significant…

December 2007

  • Media ReleaseDec 09, 2007
    Photo: New Data Show Gleevec® Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment
    - Risk of disease progression continues to drop from the second year of treatment; no patients taking Gleevec in sixth year progressed from initial disease phase- Long-term survival trend may suggest…

August 2006

  • Media ReleaseAug 17, 2006
    News Release 1 Headline
    News Release 1 Sub-HeadlineNews Release 1 Body Copy

August 2005

  • Media ReleaseAug 17, 2005
    2005 Release
    2005 Release SubHeadlineBody Copy Here

August 2004

  • Media ReleaseAug 17, 2004
    2004 Release
    2004 Release SubHeadlineBody Copy

Pagination

  • ‹ Previous page
  • 1
  • …
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30

Novartis United States

Navigate Novartis
  • Patients & Caregivers
  • Healthcare Professionals
  • ESG
  • News
  • Careers
Media Center
  • News Archive
  • Statements
  • Stories
Our Portfolio
  • Novartis Clinical Pipeline
  • Novartis Product Portfolio
Other Novartis US Websites
  • Oncology HCP Resources
  • Gene Therapy Network
  • Medical Information
  • Sandoz
  • Global Site
Footer Bottom
© 2023 Novartis Pharmaceuticals Corporation
  • Terms of Use
  • Privacy Policy
  • Contacts
  • Site Map
  • Web Accessibility
Novartis Site Directory
This site is intended for US Residents Only